Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Sage wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Raloxifene (Evista) and Sage have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.
any
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
300–600 mg standardized extract daily
With breakfast, With dinner (split dosing)
Standardized extract (300–600 mg, 2.5% rosmarinic acid)
Months to years
Years
Throughout use
Throughout use
4–8 weeks
4–8 weeks
4–8 weeks
8–12 weeks
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease.
CNS Neuroscience & Therapeutics (2014) · Systematic review
Multiple clinical trials demonstrated improvements in memory and attention in healthy young adults following acute and chronic Salvia officinalis or Salvia lavandulaefolia administration.
Exploring the therapeutic impact of Salvia officinalis on lipid and oxidative stress markers in patients with polycystic ovary syndrome - a randomized placebo-controlled clinical trial.
BMC Complementary Medicine and Therapies (2025) · Rct · n=60
Women with PCOS receiving Salvia officinalis extract showed significant reductions in total cholesterol, LDL cholesterol, and triglycerides compared to the placebo group.
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease
J Clin Pharm Ther (2003) · Rct · n=42
Significant improvement in ADAS-cog and CDR-SB scores vs placebo (P<0.003)
Based on multiple RCTs showing improvements in word recall, working memory, and attention. Effects varied by specific cognitive domain and population. Most studies used standardized extracts.
AI-estimated from published studies. Interpret as directional guidance.
Sage has a higher evidence score (6/10 vs 5.3/10) and wins in 2 of 3 categories.
No known interactions between Raloxifene (Evista) and Sage have been documented in our database. However, always consult a healthcare provider before combining supplements.